P/E at 37.08 vs Industry's 36.59: What the Data Shows for Sun Pharmaceutical Industries Ltd

Valuation Picture: Premium but in Line with Industry

The current P/E of 37.08 for Sun Pharmaceutical Industries Ltd sits slightly above the Pharmaceuticals & Biotechnology industry average of 36.59. This premium, though not excessive, suggests that investors are willing to pay a marginally higher price for the company’s earnings relative to its peers. Such a valuation often reflects expectations of stable earnings growth or superior business fundamentals. However, the premium is narrow enough to warrant scrutiny — Sun Pharma is not trading at a valuation outlier level, which tempers concerns about overvaluation.

Given the sector’s mixed result performance so far this earnings season — with 8 stocks positive, 8 flat, and 3 negative out of 19 — the valuation premium may also reflect relative resilience in Sun Pharmaceutical Industries Ltd’s earnings quality and market position. Sun Pharma’s market capitalisation of ₹4,68,530 crores confirms its status as a large-cap stalwart within the sector.

Performance Across Timeframes: Strong Long-Term Gains, Mixed Short-Term Signals

Examining the stock’s returns reveals a divergence between longer and shorter timeframes. Over one year, Sun Pharmaceutical Industries Ltd has delivered a robust 20.32% gain, significantly outperforming the Sensex’s 2.90% decline. This outperformance extends over three and five years, with returns of 71.36% and 148.95% respectively, compared to the Sensex’s 19.81% and 43.53%. However, the 10-year return of 139.86% trails the Sensex’s 180.92%, indicating a relative underperformance over the longest horizon.

In contrast, the short-term momentum is less convincing. The stock has declined 0.64% today, underperforming the Sensex’s 0.36% fall. Over the past week, it has lost 1.01%, again lagging the Sensex’s 0.21% drop. The one-month return is a modest 0.26%, slightly behind the Sensex’s 0.89%, while the three-month gain of 3.62% narrowly outpaces the Sensex’s 2.96%. This pattern suggests that while the stock remains resilient relative to the market in the medium term, recent trading sessions have seen some profit-taking or consolidation — Sun Pharma’s short-term momentum is clearly under pressure, raising the question is this a temporary pause or a sign of deeper weakness?

Moving Average Configuration: Mixed Technical Signals

The technical picture for Sun Pharmaceutical Industries Ltd is equally nuanced. The stock currently trades above its 50-day, 100-day, and 200-day moving averages, indicating that the medium to long-term trend remains positive. However, it is below its 5-day and 20-day moving averages, signalling short-term weakness or a pullback within the broader uptrend. This configuration often points to a recent correction or consolidation phase after a period of gains.

The stock’s recent two-day consecutive gain was reversed today with a 0.64% decline, suggesting some profit-taking or hesitation among traders. This pattern — above longer-term averages but below short-term ones — can be interpreted as a pause in momentum rather than a full trend reversal. Is this a genuine recovery or a dead-cat bounce? — the moving average configuration provides the clearest answer.

Sector Context: Mixed Results Reflect Industry Challenges

The Pharmaceuticals & Biotechnology sector has delivered a mixed bag of results in the current reporting cycle. Out of 19 stocks that have declared results, 8 posted positive outcomes, 8 were flat, and 3 reported negative results. This distribution highlights the sector’s uneven performance and the challenges faced by companies amid regulatory pressures, pricing dynamics, and global supply chain issues.

Within this context, Sun Pharmaceutical Industries Ltd’s ability to maintain a valuation premium and deliver solid long-term returns is noteworthy. The stock’s resilience relative to peers and the broader market underscores its standing as a key player in the sector. What does this mean for investors looking to navigate sector volatility?

Rating Context: Previously Rated Hold, Now Reassessed

On 8 June 2026, the rating for Sun Pharmaceutical Industries Ltd was updated from its previous Hold status by MarketsMOJO. The reassessment reflects the evolving valuation and performance data, including the stock’s premium P/E, strong long-term returns, and mixed short-term momentum. The Mojo Score stands at 74.0, indicating a favourable overall assessment, though the current rating itself is not disclosed.

This update invites investors to consider the implications of the valuation-performance tension and the technical signals in their decision-making process — should investors in Sun Pharmaceutical Industries Ltd hold, buy more, or reconsider?

Conclusion: A Balanced View from Valuation to Technicals

The data for Sun Pharmaceutical Industries Ltd paints a picture of a large-cap pharmaceutical stock trading at a slight premium to its industry peers, supported by strong long-term returns and a solid market capitalisation. However, recent short-term underperformance and a mixed moving average configuration suggest caution amid ongoing sector challenges.

Investors must weigh the valuation premium against the stock’s recent momentum and sector dynamics — what is the current rating? The reassessment from a previous Hold status signals a shift in the analytical view, underscoring the importance of monitoring both fundamental and technical indicators closely.

Get 33% Off on our 1 Year Plan - Limited Period Only! Start Today